Brief Report: Switching to DOR/3TC/TDF Maintains HIV-1 Virologic Suppression Through Week 144 in the DRIVE-SHIFT Trial

por Kumar, Princy, Johnson, Margaret, Molina, Jean-Michel, Rizzardini, Giuliano, Cahn, Pedro, Bickel, Markus, Wan, Hong, Xu, Zhi Jin, Morais, Cristiana, Sklar, Peter, Greaves, Wayne
Publicado 2021

Microfluidic Capture of Mycobacterium tuberculosis from Clinical Samples for Culture-Free Whole-Genome Sequencing

por Ismail, Nabila, Dippenaar, Anzaan, Morgan, George, Grobbelaar, Melanie, Wells, Felicia, Caffry, Jessica, Morais, Cristiana, Gizynski, Krzysztof, McGurk, David, Boada, Eduardo, Murton, Heather, Warren, Robin M., Van Rie, Annelies
Publicado 2023

LB2. Switch to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial

por Kumar, Princy, Johnson, Margaret, Molina, Jean-Michel, Rizzardini, Giuliano, Cahn, Pedro, Bickel, Markus, Mallolas, Josep, Zhou, Yan, Morais, Cristiana, Kumar, Sushma, Sklar, Peter, Hanna, George J, Hwang, Carey, Greaves, Wayne
Publicado 2018

Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial

por Johnson, Margaret, Kumar, Princy, Molina, Jean-Michel, Rizzardini, Giuliano, Cahn, Pedro, Bickel, Markus, Mallolas, Josep, Zhou, Yan, Morais, Cristiana, Kumar, Sushma, Sklar, Peter, Hanna, George J., Hwang, Carey, Greaves, Wayne
Publicado 2019